IGF-1 LR3 vs Sermorelin Which Better Comparison: Protocol Variables
Primary Mechanism Direct IGF-1 receptor agonist—binds IGF-1R on target tissues GHRH analog—stimulates pituitary GH release, which triggers hepatic IGF-1 synthesis IGF-1 LR3 bypasses upstream regulation entirely; Sermorelin preserves natural axis function Half-
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Direct IGF-1 receptor agonist—binds IGF-1R on target tissues
- GHRH analog—stimulates pituitary GH release, which triggers hepatic IGF-1 synthesis
- IGF-1 LR3 bypasses upstream regulation entirely; Sermorelin preserves natural axis function
- Half-Life
- 20–30 hours (extended by reduced IGFBP binding)
- 8–12 minutes (rapid proteolytic cleavage)
- IGF-1 LR3 allows once-daily dosing; Sermorelin requires multiple daily administrations or continuous infusion for sustained effect
- Dependence on Pituitary Function
- None—works independent of GH secretion or pituitary integrity
- Absolute—requires functional somatotrophs and intact GHRH receptors
- IGF-1 LR3 is the only option in models with pituitary dysfunction, hypophysectomy, or GHRH receptor knockout
- Feedback Regulation
- Bypasses negative feedback—does not suppress endogenous GH or IGF-1 production initially
- Subject to physiological feedback—rising GH/IGF-1 inhibits further secretion
- Sermorelin preserves pulsatile GH secretion patterns; IGF-1 LR3 delivers constant receptor activation
- Tissue Selectivity
- Non-selective—activates IGF-1R wherever expressed (muscle, adipose, liver, CNS)
- Indirect—selectivity determined by GH receptor distribution and hepatic IGF-1 synthesis capacity
- IGF-1 LR3 produces systemic receptor activation; Sermorelin effect is filtered through hepatic IGF-1 production
- Storage & Reconstitution
- Lyophilized powder stable at −20°C; reconstitute with bacteriostatic water, refrigerate at 2–8°C post-mixing
- Both require identical cold-chain handling—temperature excursions above 8°C cause irreversible protein denaturation